Vor Biopharma (VOR) Return on Capital Employed (2021 - 2026)
Vor Biopharma (VOR) reported Return on Capital Employed of 79.58% for Q1 2026, up 3210.0% year-over-year from 2.4% in Q1 2025, and up 36.83% quarter-over-quarter from 125.98% in Q4 2025.
Vor Biopharma (VOR) Return on Capital Employed (2021 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 6 years of Return on Capital Employed data on file, last reported at 79.58% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 79.58%, up 3210.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 79.58% (up 3210.0% YoY), and the FY2025 annual result was 133.52%, down 5374.0% from the prior year.
- Return on Capital Employed grew to 79.58% in Q1 2026 per VOR's latest filing, from 125.98% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 35.45% in Q1 2022 and troughed at 372.73% in Q2 2025.
- A 5-year average of 96.21% and a median of 75.54% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 28391 bps in 2025, then surged 3210 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 38.96% in 2022, then sank by 66 bps to 64.63% in 2023, then sank by 69 bps to 109.34% in 2024, then decreased by 15 bps to 125.98% in 2025, then jumped by 37 bps to 79.58% in 2026.
- Business Quant data shows VOR's Return on Capital Employed at 79.58% in Q1 2026, 125.98% in Q4 2025, and 213.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Vor Biopharma | 627.54 Mn | 627.54 Mn | - | -79.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.58% |
| Dec 31, 2025 | -125.98% |
| Sep 30, 2025 | -213.41% |
| Jun 30, 2025 | -372.73% |
| Mar 31, 2025 | -111.68% |
| Dec 31, 2024 | -109.34% |
| Sep 30, 2024 | -103.10% |
| Jun 30, 2024 | -88.82% |
| Mar 31, 2024 | -75.54% |
| Dec 31, 2023 | -64.63% |
| Sep 30, 2023 | -55.34% |
| Jun 30, 2023 | -44.30% |
| Mar 31, 2023 | -36.63% |
| Dec 31, 2022 | -38.96% |
| Sep 30, 2022 | -42.56% |
| Jun 30, 2022 | -37.53% |
| Mar 31, 2022 | -35.45% |
| Dec 31, 2021 | -28.70% |
| Sep 30, 2021 | -25.76% |
| Jun 30, 2021 | -21.60% |